Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Antibody-mediated rejection of the cardiac allograft: where do we stand in 2012? CURRENT OPINION IN ORGAN TRANSPLANTATION Berry, G. J. 2012; 17 (3): 303-308

Abstract

The review will discuss the current pathological criteria for the diagnosis and classification of antibody-mediated rejection (AMR) in the cardiac allograft.Until recently, the diagnosis of AMR required clinical dysfunction, presence of donor specific antibodies and pathological alterations. The concept of asymptomatic AMR and its adverse long-term outcomes created, in part the need to reevaluate diagnostic criteria. The results of a recent consensus meeting sponsored by International Society For Heart And Lung Transplantation are discussed.The diagnosis of AMR rests on histopathological and immunophenotypic findings. These provide the basis for a new grading scheme.

View details for DOI 10.1097/MOT.0b013e328353660f

View details for Web of Science ID 000303826900015

View details for PubMedID 22498650